US 12,122,841 B2
Human CGRP receptor binding proteins
Thomas C. Boone, Newbury Park, CA (US); David W. Brankow, Northridge, CA (US); Colin V. Gegg, Jr., Camarillo, CA (US); Shaw-Fen Sylvia Hu, Thousand Oaks, CA (US); Chadwick T. King, North Vancouver (CA); Hsieng Sen Lu, Westlake Village, CA (US); Licheng Shi, Newbury Park, CA (US); and Cen Xu, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Dec. 3, 2020, as Appl. No. 17/111,442.
Application 17/111,442 is a division of application No. 15/824,827, filed on Nov. 28, 2017, abandoned.
Application 14/752,493 is a division of application No. 12/642,711, filed on Dec. 18, 2009, granted, now 9,102,731, issued on Aug. 11, 2015.
Application 15/824,827 is a continuation of application No. 14/752,493, filed on Jun. 26, 2015, granted, now 9,862,771, issued on Jan. 9, 2018.
Claims priority of provisional application 61/264,622, filed on Nov. 25, 2009.
Claims priority of provisional application 61/203,569, filed on Dec. 23, 2008.
Prior Publication US 2021/0179722 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 39/39533 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01)] 18 Claims
 
1. An isolated polynucleotide encoding a heavy chain polypeptide and a light chain polypeptide of a monoclonal antibody that specifically binds to human calcitonin gene-related peptide (CGRP) receptor, wherein:
(i) the heavy chain polypeptide comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1 comprises the sequence of SEQ ID NO: 73, CDRH2 comprises the sequence of SEQ ID NO: 74, and CDRH3 comprises the sequence of SEQ ID NO: 75; and
(ii) the light chain polypeptide comprises a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1 comprises the sequence of SEQ ID NO: 42, CDRL2 comprises the sequence of SEQ ID NO: 43, and CDRL3 comprises the sequence of SEQ ID NO: 44.